Drug Profile
Research programme: CCR5 antagonists - Kemia
Latest Information Update: 26 Feb 2008
Price :
$50
*
At a glance
- Originator Kemia
- Class
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 22 Jun 2005 Kémia's CCR5 antagonists programme is available for partnering (http://www.kemia.com)
- 22 Jun 2005 Preclinical trials in HIV infections treatment in USA (PO)